EverythingALS launches AI platform to accelerate ALS research
EverythingALS has introduced a platform aimed at advancing amyotrophic lateral sclerosis (ALS) research using artificial intelligence (AI) and…
Articles by Mary Chapman
Advancing brain-computer interfaces is new collaboration’s aim
Researchers at Mass General Brigham have started an effort to develop brain-computer interfaces (BCI) for people with neurological diseases or…
Animated film aims to help young audiences understand ALS diagnosis
A disorder such as amyotrophic lateral sclerosis (ALS) can be confusing and traumatic for children, particularly if the person with…
ALS groups seek to help shape 2025 Congressional funding priorities
Some 20 U.S. organizations with a focus on amyotrophic lateral sclerosis (ALS) have put their names on a letter…
ALS Association granted $58M in largest single donation ever
An unprecedented $58 million donation to the ALS Association is a “beacon of hope” for the amyotrophic lateral…
Former ALS Association affiliate is now ALS United Greater New York
To reflect a new era of commitment and determination in the fight against amyotrophic lateral sclerosis…
University of Illinois recorded voice project recruiting ALS patients
An initiative at a University of Illinois campus that aims to improve voice recognition software for people with speech difficulties…
LifeArc grant to fund research into repurposing therapies for MND
LifeArc, a U.K.-based independent medical research charity, is offering £5 million (about $6 million) to scientists around the world…
Radicava Oral Suspension added to drug plans of 2 Canadian provinces
Two Canadian provinces — Prince Edward Island, and Newfoundland and Labrador — are covering the cost of the oral formulation…
ProJenX receives $15M in funding to further develop prosetin for ALS
The biotechnology company ProJenX recently received $15 million in funding to advance its experimental oral treatment prosetin for…